Pfizer/BioNTech Get Ready For London Court Battle With Moderna Over COVID-19 Vaccine Patents
- A High Court battle between Pfizer Inc (NYSE: PFE), its partner BioNTech SE (NASDAQ: BNTX) locked in a dispute with the rival COVID-19 vaccine maker Moderna Inc (NASDAQ: MRNA) over patents for vaccine technology is set to be heard in London next year.
- In August, Moderna filed patent infringement lawsuits against Pfizer/BioNTech in the U.S. and Germany.
- Moderna said that Pfizer/BioNTech's COVID-19 vaccine infringes patents filed between 2010 and 2016 covering foundational mRNA technology, which is critical in creating Moderna's mRNA COVID-19 vaccine.
- Pfizer and BioNTech said they developed their vaccine independently, rejecting Moderna's patent claims.
- In its lawsuit, Moderna asked for an undisclosed amount of money damages from Pfizer COVID-19 vaccines sold since March last year.
- The case reached London's High Court for the first time for a preliminary hearing on Thursday, Reuters reported, ahead of a trial due to take place in April 2024.
- Pfizer and BioNTech sued Moderna in London in September, seeking to revoke two of Moderna's patents concerning its messenger RNA (mRNA) vaccines.
- CureVac NV (NASDAQ: CVAC) is involved in patent lawsuits with Pfizer and BioNTech in Germany and the U.S. and at London's High Court, where a trial is expected to occur in July 2024.
- Pfizer and BioNTech filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe patents related to the COVID-19 vaccine held by CureVac.
- Price Action: MRNA shares are down 5.69% at $162.50, PFE stock is down 0.09% at $42.91, and BNTX shares are down 1.08% at $139.86 during the premarket session on the last check Friday.
- Photo via Wikimedia Commons
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: BriefsBiotech Large Cap News Health Care Small Cap Legal General
